<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56833">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01663233</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696A2319</org_study_id>
    <nct_id>NCT01663233</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine</brief_title>
  <official_title>A Randomized, 8-week, Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Patients With Essential Hypertension Not Adequately Responsive to Amlodipine 5 mg Monotherapy Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>China: Food and Drug Administration</authority>
    <authority>Korea: Food and Drug Administration</authority>
    <authority>Malaysia: Ministry of Health</authority>
    <authority>Philippines: Bureau of Food and Drugs</authority>
    <authority>Taiwan: Center for Drug Evaluation</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess whether LCZ696 when used in combination with amlodipine will provide
      greater BP lowering benefit compared to amlodipine alone in Asian hypertensive patients not
      adequately responsive to amlodipine therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in mean 24-hour ABPM systolic blood pressure (maSBP)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure the change in mean 24 hour ambulatory systolic blood pressure (maSBP) from baseline to end of the study (week 8) in the 2 groups. A greater reduction from baseline in the LCZ696 group will indicate whether there is a positive treatment effect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean 24-hour ABPM diastolic blood pressure (maDBP)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure the change in mean 24 hour ambulatory diastolic blood pressure (maDBP) from baseline to end of the study. A reduction from baseline will indicate whether there is a positive treatment effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean sitting systolic blood pressure (msSBP)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure the change in the patient's mean sitting systolic blood pressure (msSBP) from baseline to end of the study. A reduction from baseline will indicate whether there is a positive treatment effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean sitting diastolic blood pressure (msDBP)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure the change in the patient's mean sitting diastolic blood pressure (msDBP) from baseline to end of the study. A reduction from baseline will indicate whether there is a positive treatment effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sitting pulse pressure</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measure the change in the patient's mean sitting pulse pressure from baseline to end of the study. Pulse pressure measures the difference in mean sitting systolic blood pressure and mean sitting diastolic blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving systolic and diastolic blood pressure control (&lt; 140/90 mmHg)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Percentage of patients achieving a systolic and diastolic blood pressure &lt; 140/90 mmHg is a measure of how well a given blood pressure treatment can achieve a given blood pressure target or goal. Patient that achieve the target blood pressure will be determined based on the mean sitting diastolic and systolic blood measurements taken at the end of the study. If the patient BP measurement is below the above target they will be considered as a success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving successful response in msSBP (&lt; 140 mmHg or a reduction ≥ 20 mmHg from baseline)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of patients that achieve successful treatment response in the mean sitting systolic blood pressure (msSBP) of &lt; 140mmHg or a reduction ≥ 20 mmHg from baseline after completing study treatment. Patients that achieve either of the above targets will be deemed as a having a successful response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving successful response in msDBP (&lt; 90 mmHg or a reduction ≥ 10 mmHg from baseline)</measure>
    <time_frame>8 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of patients that achieve successful treatment response in the mean sitting diastolic blood pressure (msDBP) of &lt; 90mmHg or a reduction ≥ 10mmHg from baseline after completing study treatment. Patients that achieve either of the above targets will be deemed as having a successful response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse event</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Summarized statistics on adverse events will be reported under categories such as total adverse events, serious adverse events and death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>LCZ696 and amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>118 patients will first be treated to receive 5 mg of amlodipine for 4 weeks to deter if that they are not adequately responding to amlodipine (must have a systolic BP &gt;/= 145mmHg and meet all inclusion and exclusion criteria) will be randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>118 patients will first be treated to receive  5 mg of amlodipine for 4 weeks to determine if that they are not adequately responding to amlodipine (must have a systolic BP &gt;/= 145mmHg and meet all inclusion and exclusion criteria) will be randomized to receive  5 mg and placebo to LCZ696 for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <description>LCZ696 will used tablets available at a strength of 200mg. Patients will be instructed to take the prescribed medication once a day.</description>
    <arm_group_label>LCZ696 and amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.</description>
    <arm_group_label>LCZ696 and amlodipine</arm_group_label>
    <arm_group_label>Amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must have a diagnosis of hypertension:

        Untreated patients must have an msSBP ≥ 150 mmHg and &lt; 180 mmHg at both Visit 1 and Visit
        101. Pre-treated patients  must have an msSBP ≥ 145 mmHg and &lt; 180 mmHg after wash out at
        Visit 101. All patients must have an office msSBP ≥ 145 mmHg and &lt; 180 mmHg at the
        completion of the 4-week  run-in epoch (at the randomization visit (Visit 201).

        Patients must successfully complete ABPM and pass technical requirements at Visit 201.

        Exclusion Criteria:

        Malignant or severe hypertension (grade 3 of WHO classification; msDBP ≥110 mmHg and/or
        msSBP ≥ 180 mmHg).

        History of angioedema, drug-related or otherwise. History or evidence of a secondary form
        of hypertension. Transient ischemic cerebral attack (TIA) during the 12 months prior to
        Visit 1 or any history of stroke.

        History of myocardial infarction, coronary bypass surgery or PCI during the 12 months
        prior to Visit 1

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edogawa-ku</city>
        <state>Tokyo</state>
        <zip>133-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katsushika-ku</city>
        <state>Tokyo</state>
        <zip>124-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiyose</city>
        <state>Tokyo</state>
        <zip>204-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kunitachi</city>
        <state>Tokyo</state>
        <zip>186-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <zip>150-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon-Do</state>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koyang</city>
        <state>Kyunggi</state>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daegu</city>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>94300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valenzuela City</city>
        <zip>1441</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <state>Taiwan, ROC</state>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 29, 2013</lastchanged_date>
  <firstreceived_date>August 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Essential hypertension</keyword>
  <keyword>High blood pressure</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
